Gen-Probe's Analytical Service Laboratories Pass FDA Inspection
Gen-Probe’s Tepnel Pharma Service is pleased to announce that its analytical laboratories in Livingston, Scotland, have successfully passed a GMP inspection by the US Food and Drug Administration (FDA) without any “Form 483” citations. This is the second audit by the FDA since Tepnel relocated to its current facilities in 2008, and sits alongside the certification by the UK Medicines and Healthcare Products Regulatory Agency (MHRA) for GMP, GLP and GCP compliance at the site.
Carl Hull, CEO of Gen-Probe Incorporated, said, “This accomplishment reflects our long-standing corporate commitment to quality and regulatory compliance.”
Gen-Probe’s Tepnel Pharma Services is a global provider of outsourced services to the drug development industry. Tepnel specializes in providing pharmaceutical testing and research in the areas of batch release and stability testing, clinical trials support including bioanalysis and pharmacogenomics, and immunology.
Tepnel Pharma Services is an established brand of Gen-Probe Incorporated.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.
